Sanofi 13F Holdings · Q2 2026
Sanofi reported 10 securities worth $534.04M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: MGTX (30.86%), INBX (20.54%), NVAX (12.14%). Among its top 25 positions this quarter: 2 new, 1 exited.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | MGTX | MeiraGTx Holdings plc | $164.8M | 30.86% | 12.2M | Hold |
| 2 | INBX | Inhibrx Biosciences, Inc. | $109.7M | 20.54% | 1.2M | Hold |
| 3 | NVAX | Novavax | $64.8M | 12.14% | 6.9M | Hold |
| 4 | ANAB | AnaptysBio | $55.5M | 10.39% | 821,917 | Hold |
| 5 | ODTX | Odyssey Therapeutics Inc. | $37.3M | 6.98% | 2.0M | New |
| 6 | AGMB | Agomab Therapeutics NV | $36.1M | 6.76% | 2.8M | Hold |
| 7 | MPLT | MapLight Therapeutics Inc. | $32.7M | 6.12% | 912,041 | Hold |
| 8 | TRAX | First Tracks Biotherapeutics Inc. | $16.5M | 3.10% | 821,917 | New |
| 9 | IMRX | Immuneering Corp | $13.5M | 2.53% | 2.7M | Hold |
| 10 | QTTB | Q32 Bio Inc. | $3.1M | 0.58% | 244,083 | Hold |
| 11 | ELDN | Eledon | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR